Cytokinetics grants stock options and RSUs to new employees as inducements under Nasdaq rules.

Cytokinetics granted stock options for 24,784 shares, 16,429 restricted stock units (RSUs), and 2,242 performance stock units (PSUs) to 12 new employees hired in May and June 2026. The RSUs vest over three years, while the stock options vest over four years with a $71.38 exercise price. The PSUs depend on achieving two performance goals and vest partially upon certification. These grants are inducements to employment under Nasdaq Listing Rule 5635(c)(4). Cytokinetics is a biopharmaceutical company focused on cardiac muscle diseases, advancing treatments like MYQORZO® and others in clinical development.